We’ve been battling bacteria almost since the beginning of time. Superbugs have arrived and the strategy needs to change.

Key Takeaways

  • QuaraSense™ is an entirely new technology platform that will measure the signature of infectious bacteria, enabling rapid response and greater chance for stopping an infection.
  • QuaraSense™ has been prototyped successfully and is ready for final design and scale up to participate in global markets.
  • Currently a Reg D investment opportunity for accredited investors


QuaraSense™ is an entirely new technology platform that will measure the signature of infectious bacteria, enabling rapid response and greater chance for stopping an infection. Treatment efficacy may be measured on an ongoing basis. 

This will also be the first platform capable of detecting a wide range of infectious microorganisms with one test. QuaraSense™ technology is testing made simple because it samples from the environment in which the infection is suspected. The days of chasing a population of bacteria with a test tube are over.

Our mission:

Save lives, alleviate suffering and improve the world’s food supply.

Humanity has been battling bacteria almost since the beginning of time. Now we have superbugs. Our strategy needs to change.

Superbugs are expected to cost the global economy $100 trillion in health care and lost productivity by 2050 (as per the International Federation of Pharmaceutical Manufacturers & Associations, Nov 2018). 

Current methods for detection of bacteria are inadequate — this leads to billions in food production losses.

We overuse antibiotics, in part because we do not detect infections early enough and lack timely feedback on a drug’s effectiveness.

Antibiotic-resistant strains of bacteria are present in humans, animals and fish.

Markets for Quara’s Sensors for Life

Aquaculture:

Early warnings of bacteria outbreak will reduce the overuse of antibiotics.

QuaraSense™ will help reduce the more than $6 billion losses annually in global aquaculture (shrimp, salmon & others) due to disease.

QuaraView™ data services will allow users to track measurements over time and input weather, feeding and other variables.

Early disease diagnostics, biosecurity measures, and assigning budgets to mitigation and contingency are effective measures to save millions of dollars.

Human Health:

More than 700,000 people die annually around the world from superbug bacterial infections.

Rapidly sense a life-threatening infection and the need for treatment — critically important for sepsis and other infections.

Will help manage treatment by rapidly sensing the efficacy of treatment.

Will help control the spread of infectious disease that cost lives and billions in health care costs. 

Animal Health:

Veterinarians or animal owners will be able to quickly determine if their livestock or pet has a harmful bacterial infection.

Will help mitigate suffering and will reduce veterinary costs in the estimated $260 billion annual pet industry.

Approximately 70% of antibiotics in the US are given to livestock for preventative reasons – now they can be given only when a bacterial threat is present, saving millions of dollars and helping the fight against superbugs from the overuse of antibiotics.

Food Processing and Industrial Pipelines:

Will provide real-time sensor data for managing bacterial outbreaks from food-processing equipment to oil pipelines or pharmaceutical manufacturing.

Early detection of a bacterial threat will help to minimize the formationi of harmful biofilms.

Early warning will reduce costly plant shut-downs that can cost millions of dollars and do irreversible reputational damage.

The views presented in this document are for discussion purposes only. Quara Devices Inc. “The Company” is not advocating any of the courses of action presented in it, which are being presented solely to illustrate a range of available options. This analysis is presented on the understanding that, apart from showing this document to those of your officers, employees or advisers who are engaged in reviewing it on your behalf, its contents will not be reproduced, redistributed or passed on, directly or indirectly, by you to any other person or published, in whole or in part, for any purpose without our written permission. This document does not constitute or form part of any offer for purchase, sale or subscription of, or solicitation or invitation of any offer to buy, sell or to subscribe for, any securities nor may it or any part of it be relied on in connection with any contract or commitment whatsoever. If you do not have professional experience in matters relating to investments you should not act or rely on it, and you should return this document. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this document you agree to be bound by the terms of this notice. This document has been prepared from information which is believed at the date of this document to be reliable. Phrases like "expects," "believes,” "anticipates" and similar phrases do not constitute warranties or guarantees of any kind, expressed or implied. The information in this document is subject to change without notice. We undertake no responsibility or obligation to provide you with any additional information or to update the document or to correct any inaccuracies in it that may become apparent. The information in this document must not be used as the basis for any prescribing decisions and may not represent the approved label in all territories. Our affiliate and subsidiary companies retain the right to request the return of this document at any time. The Company’s affiliate and subsidiary companies expressly disclaim any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this document or any written or oral communication concerning it or its subject matter.

Disclosures

THE COMPANY HAS NOT COMMENCED ITS PLANNED OFFERING UNDER REGULATION A OF THE SECURITIES ACT. NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED FOR THAT PLANNED OFFERING, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.


Key Takeaways

  • QuaraSense™ is an entirely new technology platform that will measure the signature of infectious bacteria, enabling rapid response and greater chance for stopping an infection.
  • QuaraSense™ has been prototyped successfully and is ready for final design and scale up to participate in global markets.
  • Currently a Reg D investment opportunity for accredited investors

Contacts

Steven Eror
seror@quarainc.com
801-631-7288
Chief Executive Officer

Media Gallery

Video Gallery

The first handheld sensor to detect bacterial infections in minutes to save lives, alleviate suffering and improve the world’s food supply.
View on Youtube

Files

Related Bios

Steven C. Eror
Chief Executive Officer
Mr. Eror is an experienced Chief Executive Officer, Director and Investor in public and private companies with successes in the healthcare industry in cancer, inflammation and infection control. He is a strong business builder and business development professional with specific experience in Predictive Analytics, Drug Delivery, Medical Devices, Business Development, Entrepreneurship, and Strategic Planning. Steven has a lifelong interest in technology funding and investment. His experience includes serving as CEO of ProLung, Inc., MacroMed, Inc., Consonus, Inc. and as an Adjunct Professor of Finance at the University of Utah where he received a BA in Economics and French and an MBA. He is also Fellow at the National Association of Corporate Directors.
View Full Bio>>
Rod Reum, CPA, CGA
Executive Chairman
Mr. Reum has 40 years of senior executive leadership of both public and private companies. He has played a key role in management of the financing of many enterprises up to CAD $1.3 billion dollars for one project. He has been an officer and director of several public companies assisting a number of them through the “going public” phase of their growth. He has also been instrumental in bringing several new technologies from the development stage to market in the alternative energy, military and law enforcement sectors.
View Full Bio>>
Nicolette Keith, CPA, CGA
Chief Financial Officer
Ms. Keith has been a Chief Financial Officer for private and public companies listed on the TSX Venture and the Frankfurt exchanges. In addition Ms. Keith held a senior accounting role for a public company listed on the New York Stock Exchange. Nicolette speaks three languages fluently and has a passing knowledge of several others which has served her well in the area of international business. Nicolette will provide strong leadership in the areas of regulatory reporting, capital management and international financial reporting standards.
View Full Bio>>
Dr. Ken Reardon
Chief Science Officer
Dr. Reardon is Professor and Jud and Pat Harper Chair of Chemical and Biological Engineering and holds joint appointments in several other programs at Colorado State University, including Cell and Molecular Biology and Biomedical Engineering. His research combines sensor development, bioreactor analysis, systems biology, and applied microbiology and microbial ecology. Dr. Reardon received his B.S. degree from the University of Pennsylvania and his Ph.D. from Caltech, both in chemical engineering.
View Full Bio>>
Dr. Rick Derose
Director, Product Development
Dr. DeRose has more than 25 years of experience in Ag Biotech at Syngenta and Bayer developing innovation strategies for R&D projects. He was co-inventor of the first Roundup Ready Corn varieties. Dr. DeRose received the ASPB 2017 Innovation Prize for Agricultural Technology for translating discovery research into real-world outcomes in Global Agriculture and is an Industry Fellow for the Center for Innovation Management Studies at North Carolina State University. He received a Ph.D. in Medical Microbiology and Immunology from Wake Forest School of Medicine.
View Full Bio>>
Steve Witt
President – OptiEnz Sensors
Mr. Witt has extensive leadership experience and vast knowledge of the test and measurement industry. Steve has worked in several entrepreneurial roles including Vice President of Business Development for Constant Wave, an early stage company in Colorado Springs. Steve has also been President of Compressor Controls Corporation, a global business delivering solutions for turbo-machinery control applications in the oil and gas industry, and Vice President and General Manager for Agilent Technologies in Colorado Springs, developing and delivering telecommunication test equipment.
View Full Bio>>
Dr.Tichafa Munyikwa
Director, Regulatory Affairs
Dr. Munyikwa has over 20 years’ experience at major Ag Biotech companies as a Senior Research Scientist and Global Regulatory Expert. He has worked in the fields of agribusiness, biotechnology, plant molecular and cell biology, biologicals, RNA interference, genome editing, and synthetic biology. Dr. Munyikwa received his Ph.D. in Cell and Molecular Biology from Wageningen University (The Netherlands).
View Full Bio>>
Mike Kao, CPA, CGA
VP Finance
Mr. Kao is a partner of WDM Chartered Professional Accountants, a Vancouver-based firm with over 30 years experience. Mike is proficient with both personal and corporate accounting, providing client services such as business advisory, consultancy, accounting, and tax services. WDM is registered with the Canadian Public Accountability Board, (CPAB), and the U.S. Public Company Accounting Oversight Board, (PCAOB), requiring a commitment to maintain the highest standards of professional objectivity, audit quality, and technical excellence.
View Full Bio>>